Transdermal Delivery of an mRNA‐Liposome Vaccine via Dissolving Microneedle to Preserve Vaccine Activity and Enhance Immune Activation
Advanced Science · 2026
DOI: 10.1002/advs.202522846 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Jeehye Nam und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Yonsei University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Liposomes, RNA, Messenger, mRNA Vaccines, Vaccines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Seoul Metropolitan Government, National Research Foundation of Korea.
Abstract (Originalsprache)
Although mRNA vaccines have revolutionized modern vaccinology, significant challenges persist owing to their dependence on ultra‐cold storage, patient discomfort, and logistical complications associated with intramuscular (IM) injections. Dissolving microneedles (DMNs) are a promising alternative by enabling minimally invasive transdermal administration that directly engages skin‐resident immune cells, while their fabrication compromises fragile mRNA. Moreover, previous studies have emphasized antibody‐mediated immunity rather than exploiting their capacity for strong T cell responses. In this study, we developed an mRNA‐liposome vaccine via DMN (ML‐DMN) to preserve the mRNA activity in DMN formulations and boost immune cell activation. Incorporating excipients into the formulation retained the mRNA integrity during fabrication, as demonstrated by in vitro luciferase assays. In vivo administration of ovalbumin (OVA) mRNA via ML‐DMN promoted rapid migration and activation of antigen‐presenting cells (APCs) in draining lymph nodes (dLNs) within 24 h, initiating an innate immune response. This led to robust OVA‐specific T cell activation, proliferation, and secretion of key cytokines, confirming a potent adaptive immune response with lower mRNA doses than IM injections. These results suggest that ML‐DMN systems have significant potential to overcome current mRNA vaccine limitations by improving mRNA integration and immune cell targeting, offering a viable strategy for future vaccine development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotechnology, Yonsei University, Seoul, Republic of Korea.
- Department of Biochemistry, Yonsei University, Seoul, Republic of Korea.
- Department of Integrative Biotechnology, Yonsei University, Inchon, Republic of Korea.
- JUVIC Inc., Seoul, Republic of Korea.
ORCID-Profile: Jeehye Nam, Hyungil Jung
Förderung
- Ministry of Education
- Seoul Metropolitan Government
- National Research Foundation of Korea
- Korea Health Industry Development Institute
- Ministry of Health and Welfare
- Ministry of Science and ICT, South Korea
- Korea Basic Science Institute
- Brain Korea 21 (BK21) FOUR program
Zitieren
APA
Nam, J., Ahn, J., Shin, J., Lee, N., Lee, Y., Cho, S. M., Kim, P., Kang, G., Ha, S. J., & Jung, H. (2026). Transdermal Delivery of an mRNA‐Liposome Vaccine via Dissolving Microneedle to Preserve Vaccine Activity and Enhance Immune Activation. Advanced Science. https://doi.org/10.1002/advs.202522846
Vancouver
Nam J, Ahn J, Shin J, Lee N, Lee Y, Cho SM, et al. Transdermal Delivery of an mRNA‐Liposome Vaccine via Dissolving Microneedle to Preserve Vaccine Activity and Enhance Immune Activation. Advanced Science. 2026. doi:10.1002/advs.202522846
BibTeX
@article{Nam2026,
author = {Nam, Jeehye and Ahn, JiWon and Shin, Jiwoo and Lee, Nahong and Lee, Youjin and Cho, Sung Min and Kim, Paul and Kang, Geonwoo and Ha, Sang-Jun and Jung, Hyungil},
title = {Transdermal Delivery of an mRNA‐Liposome Vaccine via Dissolving Microneedle to Preserve Vaccine Activity and Enhance Immune Activation},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202522846}
}
EUVIMED